Multiple Myeloma is a typical example of a neoplasm that shows significant differences in incidence, age of onset, type, and frequency of genetic...

Multiple myeloma (MM) is the second most common hematologic malignancy in the world and accounts for 15% of primary hemocytopathies, with an ever...

Multiple myeloma (MM) is characterized by excessive production of monoclonal immunoglobulins (M proteins).

Multiple myeloma (MM) is characterized by the clonal expansion of plasma cells and the excretion of a monoclonal immunoglobulin (M-protein), or...

Multiple myeloma (MM) is a heterogeneous neoplasm accounting for the second most prevalent hematologic disorder.

Randomised controlled trials comparing the effect of exercise interventions with usual care in adults with a diagnosis of multiple myeloma.

Recent advances in the genomic and molecular characterization of PTCL, with enhanced understanding of pathobiology, have translated into significant...

Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities...

Therefore, clinical management is often based on this limited literature and extrapolation of data from the more common, nodal T-cell lymphomas in...

Multiple myeloma (MM) is a hematological malignancy that develops over years from the asymptomatic precursors, monoclonal gammopathy of undetermined...

The extranodal mature T-cell and NK-cell lymphomas and lymphoproliferative disorders represent a unique group of rare neoplasms with both overlapping...

Measurable (minimal) residual disease (MRD) has already proven to be one of the most important prognostic factors in multiple myeloma (MM).